Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H M Prince

Showing results (71-80 of 151) with videos related to

Pageof 16
Sort By:
Leukemia & Lymphoma|October 21, 2005
Cardiovascular toxicity is increased, but manageable, during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for patients aged 60 years and olderL R Mileshkin, J F Seymour, M M Wolf, et al.
European Journal of Haematology|September 3, 2003
Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumabG A Kennedy, J F Seymour, M Wolf, et al.
The British Journal of Dermatology|March 20, 2014
Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now?J J Scarisbrick, Y H Kim, S J Whittaker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 1997
Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantationC Girouard, J Dufresne, K Imrie, et al.
The British Journal of Dermatology|September 13, 2019
A comparative analysis of histone deacetylase inhibitors for the treatment of mycosis fungoides and Sézary syndromeT Papps, C McCormack, O Buelens, et al.
Leukemia|March 3, 2004
Predictive factors for successful stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabineS J Morgan, J F Seymour, A Grigg, et al.
Leukemia & Lymphoma|July 31, 1998
Prognostic markers of disease activity in Hodgkin's diseaseA J Martinow, K Yuen, I A Cooper, et al.
Annals of Hematology|November 8, 2006
The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphomaD S Ritchie, J F Seymour, A P Grigg, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|October 2, 2014
Immunogenicity and safety of a two-dose live attenuated varicella vaccine given to adults following autologous hematopoietic stem cell transplantationJ Sasadeusz, H M Prince, A Schwarer, et al.
British Journal of Haematology|April 1, 1996
Peripheral blood progenitor cell collections in multiple myeloma: predictors and management of inadequate collectionsH M Prince, K Imrie, D R Sutherland, et al.
Pageof 16

Showing results (71-80 of 151) with videos related to

Sort By:
Pageof 16
Leukemia & Lymphoma|October 21, 2005
Cardiovascular toxicity is increased, but manageable, during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for patients aged 60 years and olderL R Mileshkin, J F Seymour, M M Wolf, et al.
European Journal of Haematology|September 3, 2003
Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumabG A Kennedy, J F Seymour, M Wolf, et al.
The British Journal of Dermatology|March 20, 2014
Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now?J J Scarisbrick, Y H Kim, S J Whittaker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 1997
Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantationC Girouard, J Dufresne, K Imrie, et al.
The British Journal of Dermatology|September 13, 2019
A comparative analysis of histone deacetylase inhibitors for the treatment of mycosis fungoides and Sézary syndromeT Papps, C McCormack, O Buelens, et al.
Leukemia|March 3, 2004
Predictive factors for successful stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabineS J Morgan, J F Seymour, A Grigg, et al.
Leukemia & Lymphoma|July 31, 1998
Prognostic markers of disease activity in Hodgkin's diseaseA J Martinow, K Yuen, I A Cooper, et al.
Annals of Hematology|November 8, 2006
The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphomaD S Ritchie, J F Seymour, A P Grigg, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|October 2, 2014
Immunogenicity and safety of a two-dose live attenuated varicella vaccine given to adults following autologous hematopoietic stem cell transplantationJ Sasadeusz, H M Prince, A Schwarer, et al.
British Journal of Haematology|April 1, 1996
Peripheral blood progenitor cell collections in multiple myeloma: predictors and management of inadequate collectionsH M Prince, K Imrie, D R Sutherland, et al.
Pageof 16